			Home About us Contact

Inclusion-body Myositis (inclusion-body + myositi)

Distribution by Scientific Domains

Medical Sciences	85%

Selected Abstracts

Accumulation of amyloid-, protein in exocrine glands of transgenic mice overexpressing a carboxyl terminal portion of amyloid protein precursor

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Issue 4 2000
Ken-Ichiro Fukuchi
Amyloid-, protein (A,) and its precursor (,PP) play important roles in the pathogenesis of Alzheimer disease and inclusion-body myositis. In humans, A, deposits are found in brain, skeletal muscle, and skin. Therefore, we have investigated possible A, deposits in multiple tissues of two transgenic mouse lines overexpressing the signal plus A,-bearing 99-amino acid carboxyl terminal sequences of ,PP under the control of a cytomegalovirus enhancer/,-actin promoter. One of the lines developed A,-immunoreactive intracellular deposits consistently in the pancreas and lacrimal gland, and occasionally in gastric, DeSteno's, and lingual glands. Although the A, deposits increased during ageing and degenerative changes of the tissues were observed, little or no extracellular A, deposits were observed up to the age of 25 months. These lines of transgenic mice are useful for studying the molecular mechanisms of development and clearance of intracellular A, deposits. [source]

Cystatin C colocalizes with amyloid-, and coimmunoprecipitates with amyloid-, precursor protein in sporadic inclusion-body myositis muscles

JOURNAL OF NEUROCHEMISTRY, Issue 6 2003
Gaetano Vattemi
Abstract Cystatin C (CC), an endogenous cysteine protease inhibitor, is accumulated within amyloid-, (A,) amyloid deposits in Alzheimer's disease (AD) brain and was proposed to play a role in the AD pathogenesis. Because the chemo-morphologic muscle phenotype of sporadic inclusion-body myositis (s-IBM) has several similarities with the phenotype of AD brain, including abnormal accumulation of A, deposits, we studied expression and localization of CC in muscle biopsies of 10 s-IBM, and 16 disease- and five normal-control muscle biopsies. Physical interaction of CC with amyloid-, precursor protein (A,PP) was studied by a combined immunoprecipitation/immunoblotting technique in the s-IBM muscle biopsies and in A,PP-overexpressing cultured human muscle fibers. In all s-IBM muscle biopsies, CC-immunoreactivity either colocalized with, or was adjacent to, the A,-immunoreactive inclusions in 80,90% of the vacuolated muscle fibers, mostly in non-vacuolated regions of their cytoplasm. Ultrastructurally, CC immunoreactivity-colocalized with A, on 6,10 nm amyloid-like fibrils and floccular material. By immunoblotting, CC expression was strongly increased in IBM muscle as compared to the controls. By immunoprecipitation/immunoblotting experiments, CC coimmunoprecipitated with A,PP, both in s-IBM muscle and in A,PP-overexpressing cultured normal human muscle fibers. Our studies (i) demonstrate for the first time that CC physically associates with A,PP, and (ii) suggest that CC may play a novel role in the s-IBM pathogenesis, possibly by influencing A,PP processing and A, deposition. [source]

Annexin expression in inflammatory myopathies

MUSCLE AND NERVE, Issue 1 2004
Stefan Probst-Cousin MD
Abstract The pathogenesis of the inflammatory myopathies is still unclear, making their treatment largely empirical. Improved understanding of the molecular mechanisms of inflammatory muscle injury may, however, lead to the development of more specific immunotherapies. To elucidate a possible pathogenic contribution of calcium-binding proteins such as the annexins, we immunohistochemically investigated muscle biopsy specimens from patients with dermatomyositis (10 cases), polymyositis (9 cases), and inclusion-body myositis (4 cases), compared to control cases comprising sarcoid myopathy (3 cases), Duchenne muscular dystrophy (DMD; 4 cases), and normal muscle (3 cases). We found expression of annexins A1, A2, A4, and A6 in the vascular endothelium of all cases. Myofibers expressed annexins A5, A6, and A7 diffusely and weakly in the cytosol, whereas annexins A5 and A7 were also particularly localized to the sarcolemma. In the inflammatory myopathies, in areas of myonecrosis in DMD, and in granulomatous lesions of sarcoid myopathy, reactivity of annexins A1, A2, A4, A5, and A6 was observed in macrophages and T-lymphocytes. Whereas the latter annexins appear to be nonspecific indicators of activation, annexin A1 upregulation may represent endogenous anti-inflammatory mechanisms that merit further investigation. Muscle Nerve 30: 102,110, 2004 [source]

Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects

MUSCLE AND NERVE, Issue 4 2003
Frank L. Mastaglia MD
Abstract The three major forms of immune-mediated inflammatory myopathy are dermatomyositis (DM), polymyositis (PM), and inclusion-body myositis (IBM). They each have distinctive clinical and histopathologic features that allow the clinician to reach a specific diagnosis in most cases. Magnetic resonance imaging is sometimes helpful, particularly if the diagnosis of IBM is suspected but has not been formally evaluated. Myositis-specific antibodies are not helpful diagnostically but may be of prognostic value; most antibodies have low sensitivity. Muscle biopsy is mandatory to confirm the diagnosis of an inflammatory myopathy and to allow unusual varieties such as eosinophilic, granulomatous, and parasitic myositis, and macrophagic myofasciitis, to be recognized. The treatment of the inflammatory myopathies remains largely empirical and relies upon the use of corticosteroids, immunosuppressive agents, and intravenous immunoglobulin, all of which have nonselective effects on the immune system. Further controlled clinical trials are required to evaluate the relative efficacy of the available therapeutic modalities particularly in combinations, and of newer immunosuppressive agents (mycophenolate mofetil and tacrolimus) and cytokine-based therapies for the treatment of resistant cases of DM, PM, and IBM. Improved understanding of the molecular mechanisms of muscle injury in the inflammatory myopathies should lead to the development of more specific forms of immunotherapy for these conditions. Muscle Nerve 27:407,425, 2003 [source]

Myostatin precursor protein is increased and associates with amyloid-, precursor protein in inclusion-body myositis culture model

NEUROPATHOLOGY & APPLIED NEUROBIOLOGY, Issue 2 2007
S. Wojcik
First page of article [source]

Expression of transglutaminase 2 does not differentiate focal myositis from generalized inflammatory myopathies

ACTA NEUROLOGICA SCANDINAVICA, Issue 6 2008
V. Macaione
Objectives,,, Idiopathic inflammatory myopathies (IIM), including dermatomyositis (DM), polymyositis (PM), sporadic inclusion-body myositis (s-IBM) and focal myositis (FM) are a heterogeneous group of autoimmune disorders of skeletal muscle. An increased transglutaminase 2 (TG2) expression has been found in DM, PM and s-IBM. The aim of our study was to investigate TG2 expression in FM in comparison with other IIM. Materials and methods,,, We re-examined tissue material we have gathered in the course of our previous studies on IIM, investigating muscle expression of TG2 in patients with FM in comparison with DM, PM and s-IBM using immunocytochemistry and real-time RT-PCR. Results,,, Immunocytochemistry revealed an increased TG2 signal in endomysial vessels, in atrophic and degenerating/regenerating muscle fibres in PM, DM, s-IBM and FM; in s-IBM, some vacuoles were immunostained too. Real-time RT-PCR study confirmed a significantly increased expression of TG2 in all IIM muscles examined. Conclusions,,, Our study demonstrates the presence of TG2 in FM muscles. The study suggests that TG2 expression does not represent a distinctive marker to differentiate FM from generalized IIM. TG2 over-expression in inflamed skeletal muscle does not seem have a pathogenetic role in such a disease, but it could represent a way to contain the inflammatory process. [source]

Defining cancer risk in dermatomyositis.

CLINICAL & EXPERIMENTAL DERMATOLOGY, Issue 4 2009
Part I
Summary The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion-body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle-specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. Clinical, serological and histological criteria can be used to define individual IIM subtypes. In the first of this two-part review series, we examine the evidence for the existence of cancer-associated myositis (CAM), and in part 2, we discuss recent discoveries that provide insight into identification of patients with DM, who may be most at risk of developing CAM. [source]